Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

Yu, Shui-Lian; Chan, Paul KS; Wong, Chun-Kwok; Szeto, Cheuk-Chun; Ho, Suzanne C; So, Karine; Yu, May MY; Yim, So-Fan; Cheung, Tak-Hong; Wong, Martin CS; Cheung, Jo LK; Yeung, Apple CM; Li, Edmund K; Tam, Lai-Shan

doi:10.1186/ar3803

Table 3 Effects of clinical variables on the TLR levels in lupus patients (continuous variable)

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

	TLR3			TLR7			TLR8			TLR9
	n	r	P	n	r	P	n	r	P	n	r	P
Clinical characteristic
SLE duration, year	46	-0.263	0.279	26	-0.187	0.214	46	0.183	0.222	46	0.064	0.672
SLEDAI score	46	-0.004	0.977	26	-0.030	0.885	46	0.161	0.284	46	0.446	0.002 ^††
Anti-dsDNA titer (> 100 IU/ml)	19	0.272	0.261	13	-0.291	0.334	19	0.498	0.030 ^†	19	-0.094	0.702
Immunosuppressive therapy
Prednisolone
Current dose, mg	36	-0.082	0.636	22	-0.164	0.466	36	0.116	0.502	36	-0.032	0.855
Cumulative dose, gm	38	-0.020	0.898	22	-0.436	0.042 ^†	38	0.102	0.542	38	0.018	0.916
Duration, months	38	-0.150	0.368	22	-0.223	0.318	38	-0.100	0.555	38	0.017	0.920
Hydroxychloroquine
Current dose, mg	16	0.261	0.329	10	-0.044	0.905	16	-0.226	0.400	16	0.052	0.848
Cumulative dose, gm	27	-0.073	0.716	15	-0.132	0.639	27	-0.193	0.335	27	-0.399	0.039 ^†
Duration, months	27	-0.106	0.598	15	-0.179	0.524	27	-0.139	0.488	22	-0.081	0.689
Azathioprine
Current dose, mg	8	-0.385	0.346	5	-0.671	0.215	8	0.462	0.249	8	-0.089	0.833
Cumulative dose, gm	25	-0.166	0.429	16	-0.012	0.966	25	-0.336	0.101	25	-0.339	0.098
Duration, months	25	-0.036	0.865	16	-0.118	0.664	25	-0.396	0.505	25	-0.440	0.028 ^†
Cyclophosphamide (oral or IV)
Current dose, mg	4	-0.316	0.684	2	N.A.	N.A.	4	-0.316	0.684	4	-0.316	0.684
Cumulative dose, gm	7	0.107	0.840	3	N.A.	N.A.	7	-0.107	0.840	7	-0.500	0.267
Duration, months	7	0.571	0.200	3	N.A.	N.A.	7	0.143	0.783	7	-0.393	0.396
Cyclosporin A
Current dose, mg	-	-	-	-	-	-	-	-	-	-	-	-
Cumulative dose, gm	9	0.783	0.013 ^†	5	0.800	0.133	9	-0.333	0.948	9	-0.283	0.463
Duration, months	9	0.200	0.613	5	0.900	0.083	9	0.167	0.678	9	0.333	0.385
Mycophenolate mofetil, gm
Current dose, mg	5	0.359	0.553	3	N.A.	N.A.	5	0.718	0.872	5	0.564	0.322
Cumulative dose, gm	8	0.071	0.935	5	-0.600	0.350	8	-0.429	0.299	8	-0.381	0.360
Duration, months	8	-0.048	0.935	5	-0.700	0.233	8	-0.548	0.171	8	-0.429	0.299

Anti-dsDNA, Anti-double stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; TLR, toll-like receptor; ^† P <0.05, ^†† P <0.01.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us